236 related articles for article (PubMed ID: 20547816)
1. Voriconazole pharmacokinetics and safety in immunocompromised children compared to adult patients.
Michael C; Bierbach U; Frenzel K; Lange T; Basara N; Niederwieser D; Mauz-Körholz C; Preiss R
Antimicrob Agents Chemother; 2010 Aug; 54(8):3225-32. PubMed ID: 20547816
[TBL] [Abstract][Full Text] [Related]
2. Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised adolescents and healthy adults.
Driscoll TA; Frangoul H; Nemecek ER; Murphey DK; Yu LC; Blumer J; Krance RA; Baruch A; Liu P
Antimicrob Agents Chemother; 2011 Dec; 55(12):5780-9. PubMed ID: 21911570
[TBL] [Abstract][Full Text] [Related]
3. Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised children and healthy adults.
Driscoll TA; Yu LC; Frangoul H; Krance RA; Nemecek E; Blumer J; Arrieta A; Graham ML; Bradfield SM; Baruch A; Liu P
Antimicrob Agents Chemother; 2011 Dec; 55(12):5770-9. PubMed ID: 21968355
[TBL] [Abstract][Full Text] [Related]
4. Voriconazole drug monitoring in the management of invasive fungal infection in immunocompromised children: a prospective study.
Soler-Palacín P; Frick MA; Martín-Nalda A; Lanaspa M; Pou L; Roselló E; de Heredia CD; Figueras C
J Antimicrob Chemother; 2012 Mar; 67(3):700-6. PubMed ID: 22190607
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children.
Walsh TJ; Driscoll T; Milligan PA; Wood ND; Schlamm H; Groll AH; Jafri H; Arrieta AC; Klein NJ; Lutsar I
Antimicrob Agents Chemother; 2010 Oct; 54(10):4116-23. PubMed ID: 20660687
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens.
Purkins L; Wood N; Ghahramani P; Greenhalgh K; Allen MJ; Kleinermans D
Antimicrob Agents Chemother; 2002 Aug; 46(8):2546-53. PubMed ID: 12121931
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration.
Walsh TJ; Karlsson MO; Driscoll T; Arguedas AG; Adamson P; Saez-Llorens X; Vora AJ; Arrieta AC; Blumer J; Lutsar I; Milligan P; Wood N
Antimicrob Agents Chemother; 2004 Jun; 48(6):2166-72. PubMed ID: 15155217
[TBL] [Abstract][Full Text] [Related]
8. Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study.
Lazarus HM; Blumer JL; Yanovich S; Schlamm H; Romero A
J Clin Pharmacol; 2002 Apr; 42(4):395-402. PubMed ID: 11936564
[TBL] [Abstract][Full Text] [Related]
9. The pharmacokinetics and safety of intravenous voriconazole - a novel wide-spectrum antifungal agent.
Purkins L; Wood N; Greenhalgh K; Eve MD; Oliver SD; Nichols D
Br J Clin Pharmacol; 2003 Dec; 56 Suppl 1(Suppl 1):2-9. PubMed ID: 14616407
[TBL] [Abstract][Full Text] [Related]
10. Monitoring of voriconazole plasma concentrations in immunocompromised paediatric patients.
Pieper S; Kolve H; Gumbinger HG; Goletz G; Würthwein G; Groll AH
J Antimicrob Chemother; 2012 Nov; 67(11):2717-24. PubMed ID: 22796890
[TBL] [Abstract][Full Text] [Related]
11. Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokinetics-based analysis of adult patients with invasive fungal infections.
Pascual A; Csajka C; Buclin T; Bolay S; Bille J; Calandra T; Marchetti O
Clin Infect Dis; 2012 Aug; 55(3):381-90. PubMed ID: 22610925
[TBL] [Abstract][Full Text] [Related]
12. Integrated population pharmacokinetic analysis of voriconazole in children, adolescents, and adults.
Friberg LE; Ravva P; Karlsson MO; Liu P
Antimicrob Agents Chemother; 2012 Jun; 56(6):3032-42. PubMed ID: 22430956
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic/pharmacodynamic profile of voriconazole.
Theuretzbacher U; Ihle F; Derendorf H
Clin Pharmacokinet; 2006; 45(7):649-63. PubMed ID: 16802848
[TBL] [Abstract][Full Text] [Related]
14. Voriconazole pharmacokinetics and pharmacodynamics in children.
Neely M; Rushing T; Kovacs A; Jelliffe R; Hoffman J
Clin Infect Dis; 2010 Jan; 50(1):27-36. PubMed ID: 19951112
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and tolerability of voriconazole and a combination oral contraceptive co-administered in healthy female subjects.
Andrews E; Damle BD; Fang A; Foster G; Crownover P; LaBadie R; Glue P
Br J Clin Pharmacol; 2008 Apr; 65(4):531-9. PubMed ID: 18294327
[TBL] [Abstract][Full Text] [Related]
16. Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children.
Walsh TJ; Lutsar I; Driscoll T; Dupont B; Roden M; Ghahramani P; Hodges M; Groll AH; Perfect JR
Pediatr Infect Dis J; 2002 Mar; 21(3):240-8. PubMed ID: 12005089
[TBL] [Abstract][Full Text] [Related]
17. Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety.
Purkins L; Wood N; Greenhalgh K; Allen MJ; Oliver SD
Br J Clin Pharmacol; 2003 Dec; 56 Suppl 1(Suppl 1):10-6. PubMed ID: 14616408
[TBL] [Abstract][Full Text] [Related]
18. Steady-state pharmacokinetic and safety profiles of voriconazole and ritonavir in healthy male subjects.
Liu P; Foster G; Gandelman K; LaBadie RR; Allison MJ; Gutierrez MJ; Sharma A
Antimicrob Agents Chemother; 2007 Oct; 51(10):3617-26. PubMed ID: 17646413
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and safety of 14 days intravenous voriconazole in allogeneic haematopoietic stem cell transplant recipients.
Brüggemann RJ; Blijlevens NM; Burger DM; Franke B; Troke PF; Donnelly JP
J Antimicrob Chemother; 2010 Jan; 65(1):107-13. PubMed ID: 19933691
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics, safety and tolerance of voriconazole in renally impaired subjects: two prospective, multicentre, open-label, parallel-group volunteer studies.
Abel S; Allan R; Gandelman K; Tomaszewski K; Webb DJ; Wood ND
Clin Drug Investig; 2008; 28(7):409-20. PubMed ID: 18544001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
